Xeltis’ RestoreX technology to be presented at TVT 2017
RestoreX technology updates will be presented this week at leading interventional cardiologist meeting, TVT 2017. Presentations will provide an overview on endogenous tissue restoration (ETR) and on its potential role in heart valve therapy and will include most recent data from the preclinical aortic valve program.
“The growing sets of RestoreX data indicate a promising future for restorative heart valve therapy, making our technology prospectively relevant for interventional cardiologist,” commented Xeltis CTO and co-founder, Martijn Cox. “Our first pulmonary valve clinical trial is underway and our aortic valve in preclinical stage is a key focus for the company,” he added.
Transcatheter Valve Therapies (TVT) is hosted annually by the Cardiovascular Research Foundation and is taking place in Chicago, USA, 14-17 June 2017. The meeting looks at new therapeutic options as well as at reviewing best clinical practices in use or under investigation.